Geneva, Switzerland. In the week ahead, the International Generic and Biosimilar Medicines Association (IGBA) will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines and focus on the importance of advancing access to these essential therapies.
The fifth Global Biosimilars Week (GBW) will run from 11-14 November 2024 on social media, supported
by the www.globalbiosimilarsweek.org website.
The campaign theme this year is Advancing Access to Biosimilars. IGBA invites patients, healthcare professionals, government organisations and other interested parties to share ideas and resources about biosimilar medicines on social media using the hashtag #GlobalBiosimilarsWeek.
The highlight of the week is a complimentary webinar on the 13th November, hosted by The Center for Biosimilars. During this event – which takes place from 15h00 to 16h30 CET / 9h00 to 10h30 EST – a panel comprised of experts from leading regulatory authorities will discuss ways to ensure a robust pipeline of biosimilar medicines to ensure patients have access to these essential, cost-effective treatments.
IGBA companies are the pioneers and global leaders in the development and marketing of biosimilar medicines. To date there have been over 1,000 biosimilar approvals around the world, covering over 10 therapeutic areas.
“Biosimilar medicine approvals have expanded, but we need purposeful biosimilar medicine policies to expand much needed access to these essential medicines for patients today and to ensure a robust pipeline of the biosimilars medicines that patients will need in the future,” said IGBA Chair Adrian Van Den Hoven
Media inquiries: Jannette Cotterell Executive Counsel Australia
+61 419 204 059
jcotterell@executivecounsel.com.au
About IGBA: The International Generic and Biosimilar medicines Association (IGBA) strengthens
cooperation between associations representing manufacturers of generic and biosimilar medicines from
around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality
assured, safe and cost-effective medicines by promoting competition and enabling innovation in the
pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details,
regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org
“The IGBA invites all stakeholders to join us in Global Biosimilars Week 2024 to discuss the importance
and benefits of advancing patient access and availability of biosimilars and share their solutions for how
to make this global priority a reality,” added Susana Almeida, Secretary General of IGBA.
